By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
Health

Regional Fistula Center established at Koohi Goth Hospital, Karachi

Last updated: October 6, 2025 11:19 pm
Irma Khan
Share
SHARE

KARACHI: In a landmark advancement for women’s health, Koohi Goth Hospital has officially launched a Regional Fistula Center, offering free and comprehensive fistula treatment to women across Pakistan. The inauguration was marked by a ceremony attended by Provincial Health Minister Azra Fazal Pechuho, representatives of UNFPA, UNICEF, and leaders from the medical and public health sectors.

At the event, Prof. Tipu Sultan, senior gynecologist at Koohi Goth, stressed that fistula care is complex and costly, yet the hospital commits to providing full services free of charge — from patient admission, surgical intervention, to post-operative care and follow-up.

Patients arriving from remote or marginalized areas will receive state-of-the-art medical support, expert surgical teams, medication, and rehabilitative aftercare—without bearing any cost. This model ensures that financial barriers do not prevent women from seeking life-changing care.

The hospital administration expects the Regional Fistula Center to benefit not only Sindh residents but women nationwide. By expanding access to fistula repair and care, the initiative aims to raise awareness of maternal health issues and enhance quality of life for affected women.

Officials and attendees hailed this step as a major milestone in Pakistan’s public health infrastructure. The center is poised to play a pivotal role in reducing the burden of obstetric fistula, restoring dignity to survivors, and improving maternal care outcomes.

What is a fistula?

An obstetric fistula is a devastating injury often resulting from prolonged or obstructed labor without timely medical intervention. It causes an abnormal opening between the birth canal and bladder or rectum, leading to incontinence of urine and/or feces and long-term physical, social, and psychological consequences. Globally, tens of thousands of new cases appear each year, disproportionately affecting women in underserved regions.

Share This Article
Email Copy Link Print
Previous Article Could Your Daily Drink Choices Hold The Secret to a Longer Life?
Next Article WHO Sounds Alarm Over Rising E-Cigarette Use Among Children
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
Dar discusses regional, bilateral issues with Central Asian leaders
Politics
July 26, 2026
Trump Holds Off on Major War Escalation Against Iran as Advisers Raise Concerns
Politics
July 26, 2026
Iran War Live Updates: U.S.-Iran Strikes Abate as War Enters Latest Crossroads
Politics
July 26, 2026
Kartik Aaryan and Anees Bazmee to Reunite for Bhool Bhulaiyaa 4? Here's What We Know
Kartik Aaryan and Anees Bazmee to Reunite for Bhool Bhulaiyaa 4? Here’s What We Know
Entertainment Headline
July 26, 2026
DeepSeek Halts Fundraising Amid Mounting Scrutiny
DeepSeek Halts Fundraising Amid Mounting Scrutiny
Headline Technology
July 26, 2026
Brazil Blocks U.S. Delegation Seeking Access to Election Systems
Brazil Blocks U.S. Delegation Seeking Access to Election Systems
Headline Politics
July 26, 2026

You Might Also Like

Health

Six Types of Cancer Rapidly Increasing Among Young People, Study

By
Neha Ashraf
Health

President Reaffirms Mental Health as National Priority

By
Irma Khan
Health

Corruption Allegations Against Nursing Officers at Mayo Hospital Spark Health Department Probe

By
Neha Ashraf
WASHINGTON: UnitedHealth has warned that the Trump administration’s planned Medicare obesity-drug pilot faces “notable challenges,” casting doubt over how smoothly the program can move ahead if major insurers stay cautious. Recent market reporting said the model depends heavily on participation from Medicare drug plans that cover most Part D enrollees, which makes the stance of large insurers especially important. The concern centers on a broader CMS effort to expand access to GLP-1 weight-loss medicines for seniors. Under CMS’s published framework, the longer-term BALANCE Model would begin in Medicare Part D in January 2027, while a temporary Medicare GLP-1 Bridge is designed to start earlier and give eligible beneficiaries short-term access before that main model begins. What makes this a little more complicated is that the short-term bridge and the longer pilot are not the same thing. CMS says the Medicare GLP-1 Bridge operates outside the normal Part D coverage and payment flow, meaning Part D sponsors are not directly involved in that bridge arrangement. In other words, insurer participation is a much bigger issue for the 2027 BALANCE rollout than for the bridge itself. That distinction matters because investors and drugmakers are watching this closely. Reports said shares of obesity-drug makers fell after UnitedHealth’s comments, largely because Medicare coverage is seen as a huge growth opportunity for drugs such as Wegovy and Zepbound. If major insurers hesitate, the program could struggle to achieve the scale CMS appears to want. There is already some evidence of resistance. MarketWatch reported that CVS Health has opted out, while UnitedHealth is still evaluating the structure and discussing possible changes with Medicare officials. That does not mean the program is dead, not yet anyway, but it does suggest the administration may need to revise the design or sweeten the terms if it wants broader insurer buy-in. The bigger backdrop here is cost. Medicare has long been wary of broad obesity-drug coverage because GLP-1 therapies are expensive and potentially involve very large patient populations. Earlier policy debates around these drugs were shaped by concerns that wide coverage could drive up federal spending sharply, even as supporters argued the medicines could reduce longer-term health costs tied to obesity. So the headline problem for CMS is pretty straightforward: it has created a short-term bridge that can move without direct Part D plan involvement, but the more ambitious long-term Medicare model still appears to need insurers on board. UnitedHealth’s warning does not shut the door, but it does signal that one of the industry’s biggest players thinks the current setup may not be ready for easy launch.
HeadlineHealth

UnitedHealth raises red flags over Medicare obesity-drug pilot

By
Mabruka Khan
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?